These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 23245996)

  • 21. Bcl-xl and Mcl-1 are the major determinants of the apoptotic response to dual PI3K and MEK blockage.
    Jokinen E; Koivunen JP
    Int J Oncol; 2015 Sep; 47(3):1103-10. PubMed ID: 26135106
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy.
    Inoue-Yamauchi A; Jeng PS; Kim K; Chen HC; Han S; Ganesan YT; Ishizawa K; Jebiwott S; Dong Y; Pietanza MC; Hellmann MD; Kris MG; Hsieh JJ; Cheng EH
    Nat Commun; 2017 Jul; 8():16078. PubMed ID: 28714472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthetic Lethality in PTEN-Mutant Prostate Cancer Is Induced by Combinatorial PI3K/Akt and BCL-XL Inhibition.
    Ren W; Joshi R; Mathew P
    Mol Cancer Res; 2016 Dec; 14(12):1176-1181. PubMed ID: 27590631
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of ABT-263 activity across a cancer cell line collection leads to a potent combination therapy for small-cell lung cancer.
    Faber AC; Farago AF; Costa C; Dastur A; Gomez-Caraballo M; Robbins R; Wagner BL; Rideout WM; Jakubik CT; Ham J; Edelman EJ; Ebi H; Yeo AT; Hata AN; Song Y; Patel NU; March RJ; Tam AT; Milano RJ; Boisvert JL; Hicks MA; Elmiligy S; Malstrom SE; Rivera MN; Harada H; Windle BE; Ramaswamy S; Benes CH; Jacks T; Engelman JA
    Proc Natl Acad Sci U S A; 2015 Mar; 112(11):E1288-96. PubMed ID: 25737542
    [TBL] [Abstract][Full Text] [Related]  

  • 25. NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivo.
    Ma Q; Gu L; Liao S; Zheng Y; Zhang S; Cao Y; Zhang J; Wang Y
    Apoptosis; 2019 Feb; 24(1-2):83-94. PubMed ID: 30515612
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bcl-2 and Bcl-xL mediate resistance to receptor tyrosine kinase-targeted therapy in lung and gastric cancer.
    Jin J; Xiong Y; Cen B
    Anticancer Drugs; 2017 Nov; 28(10):1141-1149. PubMed ID: 28885267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic KRAS-associated gene signature defines co-targeting of CDK4/6 and MEK as a viable therapeutic strategy in colorectal cancer.
    Pek M; Yatim SMJM; Chen Y; Li J; Gong M; Jiang X; Zhang F; Zheng J; Wu X; Yu Q
    Oncogene; 2017 Aug; 36(35):4975-4986. PubMed ID: 28459468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
    Shi J; Zhou Y; Huang HC; Mitchison TJ
    Cancer Res; 2011 Jul; 71(13):4518-26. PubMed ID: 21546570
    [TBL] [Abstract][Full Text] [Related]  

  • 29. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
    Lu H; Liu C; Velazquez R; Wang H; Dunkl LM; Kazic-Legueux M; Haberkorn A; Billy E; Manchado E; Brachmann SM; Moody SE; Engelman JA; Hammerman PS; Caponigro G; Mohseni M; Hao HX
    Mol Cancer Ther; 2019 Jul; 18(7):1323-1334. PubMed ID: 31068384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. STAT3 inhibitor sensitized KRAS-mutant lung cancers to RAF inhibitor by activating MEK/ERK signaling pathway.
    Wang Z; Yin M; Chu P; Lou M
    Aging (Albany NY); 2019 Sep; 11(17):7187-7196. PubMed ID: 31484165
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Novel Combination Treatment Targeting BCL-X
    Cho SY; Han JY; Na D; Kang W; Lee A; Kim J; Lee J; Min S; Kang J; Chae J; Kim JI; Park H; Lee WS; Lee C
    Mol Cancer Ther; 2017 Oct; 16(10):2178-2190. PubMed ID: 28611106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined Pan-RAF and MEK Inhibition Overcomes Multiple Resistance Mechanisms to Selective RAF Inhibitors.
    Whittaker SR; Cowley GS; Wagner S; Luo F; Root DE; Garraway LA
    Mol Cancer Ther; 2015 Dec; 14(12):2700-11. PubMed ID: 26351322
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined MEK and BCL-2/X
    Iavarone C; Zervantonakis IK; Selfors LM; Palakurthi S; Liu JF; Drapkin R; Matulonis UA; Hallberg D; Velculescu VE; Leverson JD; Sampath D; Mills GB; Brugge JS
    Mol Cancer Ther; 2019 Mar; 18(3):642-655. PubMed ID: 30679390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems.
    Shang E; Zhang Y; Shu C; Ishida CT; Bianchetti E; Westhoff MA; Karpel-Massler G; Siegelin MD
    Sci Rep; 2018 Oct; 8(1):15383. PubMed ID: 30337641
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in
    Flemington V; Davies EJ; Robinson D; Sandin LC; Delpuech O; Zhang P; Hanson L; Farrington P; Bell S; Falenta K; Gibbons FD; Lindsay N; Smith A; Wilson J; Roberts K; Tonge M; Hopcroft P; Willis SE; Roudier MP; Rooney C; Coker EA; Jaaks P; Garnett MJ; Fawell SE; Jones CD; Ward RA; Simpson I; Cosulich SC; Pease JE; Smith PD
    Mol Cancer Ther; 2021 Feb; 20(2):238-249. PubMed ID: 33273059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
    Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
    Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade.
    Williams MM; Lee L; Hicks DJ; Joly MM; Elion D; Rahman B; McKernan C; Sanchez V; Balko JM; Stricker T; Estrada MV; Cook RS
    Mol Cancer Res; 2017 Mar; 15(3):259-268. PubMed ID: 28039357
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.